According to the literature, SCLC cells with MYC amplification have been found to have sensitivity to AURKi, Alisertib (AURK-A inhibitor), and Barasertib (AURK-B inhibitor) [42,93]. The gene discussed is MYC; the disease is small cell lung carcinoma.